Next Article in Journal
Factors Associated with Hemorrhage of Melanoma Brain Metastases after Stereotactic Radiosurgery in the Era of Targeted/Immune Checkpoint Inhibitor Therapies
Next Article in Special Issue
Cell-Free DNA Analysis within the Challenges of Thyroid Cancer Management
Previous Article in Journal
Prognostic and Predictive Effects of Tumor and Plasma miR-200c-3p in Locally Advanced and Metastatic Breast Cancer
Previous Article in Special Issue
Predictors of Recurrence in Patients with Papillary Thyroid Carcinoma: Does Male Sex Matter?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 10
10.3390/cancers14102382
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis

by
Shinje Moon
1,
Ka Hee Yi
2 and
Young Joo Park
3,4,5,*
1
Department of Internal Medicine, Hallym University College of Medicine, Seoul 07440, Korea
2
Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul 07061, Korea
3
Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, Korea
4
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea
5
Genomic Medicine Institute, Medical Research Center, Seoul National University College of Medicine, Seoul 03080, Korea
*
Author to whom correspondence should be addressed.
Cancers 2022, 14(10), 2382; https://doi.org/10.3390/cancers14102382
Submission received: 27 February 2022 / Revised: 2 May 2022 / Accepted: 5 May 2022 / Published: 12 May 2022
(This article belongs to the Special Issue Thyroid Cancers)
Browse Figures
Versions Notes

Abstract

:

Simple Summary

This meta-analysis of 22 articles investigated whether thyroidectomy or radioactive iodine treatment (RAIT) in patients with differentiated thyroid cancer was associated with an increase in adverse pregnancy outcomes, such as miscarriage, preterm delivery, and congenital malformations. The results of this meta-analysis suggest that thyroid cancer treatment, including RAIT, is not associated with an increased risk of adverse pregnancy outcomes, including miscarriage, preterm labor, and congenital anomalies.

Abstract

This meta-analysis investigated whether thyroidectomy or radioactive iodine treatment (RAIT) in patients with differentiated thyroid cancer (DTC) was associated with an increase in adverse pregnancy outcomes, such as miscarriage, preterm delivery, and congenital malformations. A total of 22 articles (5 case-control and 17 case series studies) from 1262 studies identified through a literature search in the PubMed and EMBASE databases from inception up to 13 September 2021 were included. In patients with DTC who underwent thyroidectomy, the event rates for miscarriage, preterm labor, and congenital anomalies were 0.07 (95% confidence interval [CI], 0.05–0.11; 17 studies), 0.07 (95% CI, 0.05–0.09; 14 studies), and 0.03 (95% CI, 0.02–0.06; 17 studies), respectively. These results are similar to those previously reported in the general population. The risk of miscarriage or abortion was increased in patients with DTC when compared with controls without DTC (odds ratio [OR], 1.80; 95% CI, 1.28–2.53; I2 = 33%; 3 studies), while the OR values for preterm labor and the presence of congenital anomalies were 1.22 (95% CI, 0.90–1.66; I2 = 62%; five studies) and 0.73 (95% CI, 0.39–1.38; I2 = 0%; two studies) respectively, which showed no statistical significance. A subgroup analysis of patients with DTC according to RAIT revealed that the risk of miscarriage, preterm labor, or congenital anomalies was not increased in the RAIT group when compared with patients without RAIT. The results of this meta-analysis suggest that thyroid cancer treatment, including RAIT, is not associated with an increased risk of adverse pregnancy outcomes, including miscarriage, preterm labor, and congenital anomalies.

1. Introduction

According to recent cancer statistics, approximately 75% of differentiated thyroid cancer (DTC) occurs in women, with the highest incidence found in those aged 50–59 years in the United States [1]. DTC is one of the most common cancers affecting women aged 15–39 years, and recent studies have shown an increase in the incidence of DTC in this population [2]. Most DTCs have a good prognosis with a 5-year survival rate of >98% [3,4]. Despite the low mortality, recurrence is relatively common [5].
A Korean nationwide study involving patients with DTC smaller than 2 cm reported overall 5- and 10-year recurrence rates of 4.5% and 9.2%, respectively [6]. A recent meta-analysis of 31 studies on low-risk DTC showed that the pooled 10-year recurrence rate was 9.0% in patients who underwent hemithyroidectomy and 7.4% in those who underwent total thyroidectomy [7]. Moreover, recurrence more frequently occurs in younger patients, although their survival is rarely affected [8,9]. Therefore, concerns regarding undesirable health outcomes related to DTC treatment modalities, particularly in younger patients, are increasing [10].
Thyroidectomy and radioactive iodine treatment (RAIT) are standard treatments for DTC [5]. All patients who undergo total thyroidectomy and more than half of patients who undergo less-than-total thyroidectomy receive thyroid hormone replacement therapy after thyroidectomy [5], and some of them require thyroid hormone suppression therapy. Thus, the adverse effects of thyroid hormone over- or under-replacement after thyroidectomy can last a lifetime [5]. The importance of adequate thyroid hormonal status, particularly in pregnant women, has been emphasized in association with pregnancy outcomes [11].
RAIT has been administered in 45–55% of all patients with DTC [12,13,14], and several adverse events have been reported [15,16], including temporary amenorrhea/oligomenorrhea, earlier onset of menopause, infertility, and adverse pregnancy outcomes [16,17,18]. A recent meta-analysis involving four studies reported that RAIT was not associated with a decreased birthrate; however, there was significant heterogeneity among the included studies [18,19]. Considering the progressively increasing incidence of DTC in younger women, the association of thyroid cancer treatment with adverse pregnancy outcomes and infertility is one of the important issues for women with DTC.
Several case-control [14,20] and case series [21,22] studies have attempted to investigate such associations; nonetheless, the evidence regarding adverse pregnancy outcomes in patients with DTC is still inconclusive [20]. Therefore, we aimed to evaluate the incidence of adverse pregnancy outcomes, including miscarriage, preterm delivery, and congenital malformations, in patients with thyroid cancer and to investigate whether patients with DTC had an increased risk of adverse pregnancy outcomes compared with those without DTC by conducting a meticulous meta-analysis and systematic review.

2. Materials and Methods

2.1. Search Strategy

The present study was registered in the “International Platform of Registered Systematic Review and Meta-Analysis Protocols” in 2022 (INPLASY202240075) and was conducted according to PRISMA guidelines.
A literature search was conducted according to the protocol recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (Table S1). Two investigators (S.M. and Y.J.P.) refined data extraction tables prior to data extraction. These two investigators searched citation databases, including PubMed and EMBASE (from inception until 13 September 2021), and extracted data independently using the predefined tables for data extraction. Discrepancies were resolved by discussion with a third investigator (K.H.Y.). Search terms included combinations of the following: (“Pregnancy”), (“Infertility”), (“Birth”), (“abortion”), (“miscarriage”), (“preterm”) OR (“ovary”) AND (“thyroid cancer”) in the title or abstract.

2.2. Study Selection

Studies with the following characteristics were included: (1) population: pregnant women aged ≥20 years; (2) intervention: total thyroidectomy with/without RAIT or subtotal thyroidectomy; (3) comparators: pregnant women without thyroid cancer in case-control studies (there were no comparators in case series studies); (4) outcomes: miscarriage or abortion, preterm delivery, and congenital malformations; and (5) study design: case-control or case series designs using a registry of patients with thyroid cancer.
We excluded studies with the following characteristics: (1) articles on animal studies or in vivo experiments; (2) articles that included only abstracts; (3) non-original articles, including expert opinions or reviews; and (4) studies with insufficient information on adverse pregnancy outcomes.

2.3. Quality Assessment

The Newcastle–Ottawa Quality Assessment Scale was used to assess the methodological quality of case-control studies [23]. Based on eight items, a maximum of nine points were awarded to each study, categorized into three broad perspectives: selection, comparability, and exposure. Studies with a score of 7 or higher were defined as having a low risk of bias [24]; case series study designs were considered to have a high risk of bias owing to the lack of control data. Any discrepancies were resolved through a discussion with a third investigator (K.H.Y.).

2.4. Data Analyses and Statistical Methods

The event rate of studies was estimated based on the incidence of adverse pregnancy outcomes in patients with thyroid cancer. The pooled event rate was calculated for each adverse pregnancy outcome using a random-effects model. Odds ratios (ORs) and 95% confidence interval (CIs) were computed for each study using the Mantel–Haenszel method. Pooled ORs were calculated for each adverse pregnancy outcome based on thyroid cancer treatment using a random-effects model.
The heterogeneity among the studies was tested using Higgins’ I2 statistic, where I2 ≥ 50% indicated heterogeneity. Publication bias was tested using Egger’s test and a funnel plot. In addition, to evaluate the effect of RAIT on adverse pregnancy outcomes, we conducted a subgroup analysis of studies that included patients who received RAIT. All statistical analyses and graphical presentations were conducted using the Comprehensive Meta-Analysis software version 3 (Biostat Inc., Englewood, NJ, USA).

3. Results

3.1. Study Characteristics

The literature search yielded 1262 studies (PubMed: 498, EMBASE: 764). Following the exclusion of 471 duplicate studies and 769 studies that did not meet the inclusion criteria or had insufficient data, a total of 22 studies [14,20,21,22,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42] were finally included in the meta-analysis (Figure 1). The characteristics of each study are summarized in Table 1.

3.2. Risk of Bias Assessment

The Newcastle–Ottawa Quality Assessment Scale for case-control studies revealed that four [25,27,30,42] out of five case-control studies had a low or moderate risk. (Table S2). One study [31] had a high risk of bias. Five studies classified as case series studies [14,20,29,35,36] were included in subgroup analysis, which compared the risk of adverse pregnant outcomes in patients with DTC according to RAIT. Two studies [14,20] had a low or moderate risk, and three studies [29,35,36] had a high risk of bias.

3.3. Thyroid Cancer Treatment and Risk of Miscarriage or Abortion

Nine studies [22,25,29,32,33,34,38,39,41] reported obstetric history of women who underwent thyroidectomy for thyroid cancer and revealed that 63 (2.8%) of 2253 women with DTC had at least one miscarriage in their lifetime. In 17 studies [21,22,26,28,29,30,31,32,33,34,35,36,37,38,39,40,41] involving 2337 cases of pregnancy after thyroid cancer treatment, 197 miscarriages (8.2%) were reported. The event rate for miscarriage among cases of pregnancy in the random-effects model was 0.07 (95% CI, 0.05–0.11; I2 = 84.1%) (Figure 2A). In three case-control studies [25,30,31], the OR for miscarriage or abortion was 1.80 (95% CI, 1.28–2.53; I2 = 33%) in patients with DTC compared with controls (Figure 2B); however, significant publication bias was detected (Egger’s test: p = 0.05).

3.4. Thyroid Cancer Treatment and Preterm Labor

Five studies [14,25,32,34,38] reported the obstetric history of women who underwent thyroidectomy for thyroid cancer treatment and showed that 134 (3.9%) of 3466 women with DTC experienced preterm labor at least once in their lifetime. In 14 studies [20,21,26,27,30,31,32,34,35,36,37,38,40,42] with 10,237 cases of pregnancy after thyroid cancer treatment, 1167 instances of preterm labor (11.4%) were reported.
The event rate for preterm labor among cases of pregnancy in the random-effects model was 0.07 (95% CI, 0.05–0.09; I2 = 82.0%) (Figure 3A). Five case-control studies [25,27,30,31,42] were included to compare the risk of preterm labor associated with thyroid cancer treatment. The OR for preterm labor was 1.22 (95% CI, 0.90–1.66; I2 = 62%) in patients with thyroid cancer when compared with those without thyroid cancer (Figure 3B), which was not significantly different. Publication bias was not detected (Egger’s test: p = 0.56).

3.5. Thyroid Cancer Treatment and Congenital Anomalies

In 17 studies [20,22,26,28,29,30,31,32,33,34,35,36,37,38,39,40,41] with 9129 cases of pregnancy after thyroid cancer treatment, 677 cases of congenital anomalies (7.4%) were reported. The event rate in the random-effects model was 0.03 (95% CI, 0.02–0.06; I2 = 72.7%) (Figure 4A). Two case-control studies [30,31] were included to compare the risk of congenital anomalies associated with thyroid cancer treatment (Figure 4B). The OR for the presence of congenital anomalies was 0.73 (95% CI, 0.39–1.38; I2 = 0%), which was not significantly different.

3.6. Effect of RAIT on Adverse Pregnancy Outcomes

In 15 studies [22,26,28,29,30,31,32,33,34,35,36,38,39,40,41] involving 1019 cases of pregnancy after RAIT, 97 miscarriages (9.5%) were reported. The event rate among cases of pregnancy in the random-effects model was 0.09 (95% CI, 0.07–0.13; I2 = 56.3%) (Figure 5A). The OR for miscarriage or abortion was 1.08 (95% CI, 0.99–1.16; I2 = 0%) in patients who received RAIT, as compared with those without RAIT (Figure 5A), which was not significantly different [14,20,29,30,35,36]. Publication bias was not detected (Egger’s test: p = 0.29).
In 10 studies [20,26,30,31,32,34,35,36,38,40] with 3842 cases of pregnancy after thyroid cancer treatment, 461 instances of preterm labor (12.0%) were reported. The event rate among cases of pregnancy in the random-effects model was 0.08 (95% CI, 0.05–0.11; I2 = 56.8%) (Figure 5B). The OR for preterm labor was 1.09 (95% CI, 0.86–1.38; I2 = 16%) in patients who received RAIT when compared with those without RAIT (Figure 5B), which was not significantly different [14,20,30,35,36]. Publication bias was not detected (Egger’s test: p = 0.16).
In 16 studies [20,22,26,28,29,30,31,32,33,34,35,36,38,39,40,41] with 4201 cases of pregnancy after thyroid cancer treatment, 309 cases of congenital anomalies (7.3%) were reported. The event rate among cases of pregnancy in the random-effects model was 0.04 (95% CI, 0.02–0.06; I2 = 60.0%) (Figure 5C). The risk of the presence of congenital anomalies was not increased in patients with thyroid cancer who received RAIT, as compared with patients who did not receive RAIT (OR, 1.02; 95% CI, 0.87–1.20; I2 = 0%) (Figure 5C) [20,29,30,35,36]. Publication bias was not detected (Egger’s test: p = 0.69).
The subgroup analysis of studies that included patients with an interval of 1 year or more between conception and RAIT revealed that the risk of miscarriage or abortion, preterm labor, and congenital anomalies did not differ between patients who were treated with RAIT and those who were not (Figure 6).

4. Discussion

In this meta-analysis, the risk of adverse pregnancy outcomes, including miscarriage, preterm delivery, and congenital anomalies, did not differ between pregnant women with or without thyroid cancer. In the subgroup analysis, RAIT did not increase the risk of adverse pregnancy outcomes in patients with DTC treated with RAIT when compared with those who did not receive RAIT.
In the treatment of DTC, thyroidectomy and RAIT are applied as standard treatments [5]. Total thyroidectomy can lead to postoperative hypothyroidism. In addition, postoperative hypothyroidism reportedly occurs in approximately 30% of patients even after subtotal thyroidectomy [43]. Considering that many patients with DTC undergo thyroid hormone suppression therapy, these patients may experience various thyroid functional statuses (euthyroid, subclinical/overt, hyperthyroid, or hypothyroid) according to the individual thyroid-stimulating hormone target or compliance with levothyroxine [44].
Based on studies emphasizing that subclinical hyperthyroidism is not associated with maternal or neonatal complications, the American Thyroid Association recommends that patients with thyroid cancer maintain the same thyroid-stimulating hormone goal before and during pregnancy [5]. Nevertheless, epidemiological studies on the effects of thyroid dysfunction caused by thyroid hormone suppression therapy or thyroidectomy in terms of adverse pregnancy outcomes are lacking [45].
This meta-analysis with case-control studies demonstrated an increased risk of miscarriage or abortion, and this result may be biased because of the small number of studies and considering the potentially significant publication bias. In addition, although this meta-analysis showed that thyroid cancer treatment did not increase the risk of preterm labor, significant heterogeneity was noted among the included studies. Two studies showed a higher risk of miscarriage and preterm labor in patients with DTC [25,30]. Blackburn et al. reported a higher incidence of miscarriage and preterm labor in patients with DTC.
However, the hazard ratio was not significant after adjusting for comorbidities [25]. Garsi et al. also reported that patients with DTC had a significantly higher risk of miscarriage and preterm labor after receiving treatment for DTC than before treatment [30]. Considering the advanced age after treatment compared with that before treatment, the higher incidence of adverse pregnancy outcomes after DTC treatment may be the effect of advanced maternal age [30]. This meta-analysis provides data on the event rates in patients with DTC.
The event rate for miscarriage was 0.07 in patients with DTC, which is similar to those in the general population from national representative data (0.01–0.18) [46,47,48]. Four European case series studies [22,33,39,41] and one Indian case series study [34], which reported the obstetric history of women with DTC, showed that the prevalence of miscarriage at least once in their lifetime was similar to that in the general population in the EPIC study [49] or general Indian population [50]. The events rates for preterm labor were 0.07 in patients with DTC, which were similar to those in the general population (0.06–0.23) [51,52,53,54].
The event rates for congenital anomalies were 0.03 in patients with DTC, which were similar to those in the general population (0.01–0.03) [51,52,55,56]. Nonetheless, a large population-based study conducted by Kim et al. revealed a higher risk of congenital anomalies in women with DTC compared with that in the general population from the Korean National Health Insurance Service. The study by Kim et al. included more pregnant women aged >35 years than the study on the general population (34% vs. 15.9%), which could have resulted in a higher risk [20,56]. Although we could not perform subgroup analysis according to thyroid functional status, the present study provides substantial evidence that thyroid cancer treatment does not increase the risk of adverse pregnancy outcomes compared to women without DTC.
RAIT is known to be able to affect gonadal tissues [16,17,42]. In men, an association between RAIT and a transient reduction in sperm count, elevated follicle-stimulating hormone (FSH) levels, and testicular damage have been reported [16,57]. A recent longitudinal prospective study revealed a statistically significant increase in the number of chromosomal abnormalities in sperm at 3 and 13 months after RAIT with 100 mCi [58]. Therefore, contraception is usually recommended at least for 3 months in men after RAIT [5]. In addition, high radioactive iodine (RAI) activities of 500–800 mCi increased the risk of sustained elevation of FSH [5].
Therefore, the American Thyroid Association (ATA) recommends sperm banking for men who need cumulative RAI activities greater than 400 mCi [5,59]. Proper hydration, frequent urination, and avoidance of constipation may also be helpful in reducing radiation exposure to the gonads [60]. In women, RAIT has been reported to be associated with oligomenorrhea, transient secondary amenorrhea, and premature menopause [5].
About 12–31% of menstrual irregularities and 8–16% of amenorrhea [17] or a significant decrement of anti-Müllerian hormone (AMH) [18] in the first year after RAIT have been reported. Although, many previous epidemiologic studies have not found conclusive evidence for decreased fertility in these women [18,30,34,35,61], there is significant heterogeneity between studies. Research reported that RAIT was associated with delayed childbearing and reduced birthrates in a specific population of advanced age (>35 years) [19]. Therefore, in women over 35 years of age with low-risk DTC, RAIT should be carefully considered when planning pregnancy [19,62].
These women should be informed and counseled about the potential deleterious effects on fertility and fertility [63]. AMH measurement is suggested as a good option to estimate ovarian reserve for fertility patients in RAIT decision-making process, although it cannot fully estimate the risk of infertility [62]. As suggested by the American Society of Clinical Oncology, interventions for preserving fertility, including oocyte cryopreservation, may be useful particularly in women with a limited ovarian reserve [63,64], although its evidence in women with RAIT remains lacking. Further studies are warranted.
The ATA recommends that reproductive-age women receiving RAIT should undergo negative screening evaluation for pregnancy and should avoid pregnancy for 6–12 months after receiving RAI [5]. Despite these recommendations, RAI may inadvertently be administered to pregnant women because of a clinician’s negligence or false-negative pregnancy test results [65]. The effects of inadvertent exposure on embryos and fetuses vary depending on the pregnancy stage and absorbed RAI dose [65]. Exposure to RAI during the very early stage of pregnancy may result in cellular damage and embryo death although it is unlikely to induce congenital anomalies in the surviving embryos [66].
At 3–7 weeks after conception, exposure to RAI can lead to congenital anomalies, such as microcephaly, cleft palate, and genital deformities [66]. Considering that the thyroid gland is formed by 10–12 weeks of gestation, exposure to RAI after 10 weeks of gestation can result in fetal thyroid ablation [67,68,69]. Exposure after 8 weeks of gestation can impair the central nervous system. In particular, mental retardation has been frequently reported with exposure at 8–25 weeks after conception [70,71]. Additionally, exposure to RAI can increase the risk of some cancers, such as leukemia, skin cancer, lung cancer, breast cancer, and thyroid cancer [71,72].
When inadvertent exposure occurs, potassium iodide can be helpful in reducing fetal exposure to RAI within 12 h of RAI administration [65,73]. However, data on therapeutic abortion are limited [74]. During pregnancy, congenital anomalies should be closely monitored. Levothyroxine supplementation should be considered to maintain maternal thyroid hormone levels at the high end of the normal range. For neonates, thyroid function should be evaluated, and levothyroxine supplementation should be initiated to prevent any neurological impairment [65].
This meta-analysis provides data on the event rates in patients who received RAIT. The event rates in patients receiving RAIT were 0.09, 0.08, and 0.04 for miscarriage, preterm labor, and congenital anomalies, respectively, which were similar to those observed in the general population [46,47,48,51,52,53,54,55,56]. In addition, this meta-analysis with case-control studies showed that RAIT did not increase the risk of miscarriage, preterm labor, and congenital anomalies without significant heterogeneity among the included studies compared with those with DTC who did not receive RAIT.
The strengths of this study include the collection of evidence through a rigorous systematic review and meta-analysis. However, the present study has certain limitations. We could not adjust for the complications of DTC treatment, including hyperparathyroidism, the stage of DTC, and recurrence, because corresponding data were unavailable. In addition, a subgroup analysis according to total thyroidectomy or hemilobectomy, thyroid functional status, and RAIT dosage was not conducted due to the lack of data.

5. Conclusions

The meta-analysis results suggest that thyroid cancer treatment is not associated with an increased risk of adverse pregnancy outcomes. In particular, RAIT after thyroidectomy was not found to increase the risk of adverse pregnancy outcomes in patients with DTC compared with those with DTC who did not receive RAIT.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14102382/s1, Table S1. PRISMA checklist; Table S2. Quality of the included studies according to the Newcastle–Ottawa Quality Assessment Scale.

Author Contributions

Conceptualization, S.M. and Y.J.P.; Methodology, S.M. and Y.J.P.; Software, S.M. and Y.J.P.; Validation, S.M., K.H.Y. and Y.J.P.; Formal analysis, S.M.; Investigation, S.M.; Resources, S.M.; Data curation, S.M.; Writing—original draft preparation, S.M. and Y.J.P.; Writing—review and editing, S.M., K.H.Y. and Y.J.P.; Visualization, S.M.; Supervision, K.H.Y. and Y.J.P.; Project administration, Y.J.P.; Funding acquisition, Y.J.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by a research grant from Seoul National University, Seoul, Korea (grant number: 2019–1544).

Data Availability Statement

The data presented in this study are available upon reasonable request from the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. United States Cancer Statistics: Data Visualizations—Demographics. Available online: https://gis.cdc.gov/Cancer/USCS/#/Demographics/ (accessed on 16 December 2021).
  2. Scott, A.R.; Stoltzfus, K.C.; Tchelebi, L.T.; Trifiletti, D.M.; Lehrer, E.J.; Rao, P.; Bleyer, A.; Zaorsky, N.G. 2020 Trends in Cancer Incidence in US Adolescents and Young Adults, 1973–2015. JAMA Netw. Open 2020, 3, e2027738. [Google Scholar] [CrossRef] [PubMed]
  3. United States Cancer Statistics: Data Visualizations—Trends. Available online: https://gis.cdc.gov/Cancer/USCS/#/Trends/ (accessed on 16 December 2021).
  4. Choi, Y.M.; Kim, T.Y.; Jang, E.K.; Kwon, H.; Jeon, M.J.; Kim, W.G.; Shong, Y.K.; Kim, W.B. Standardized Thyroid Cancer Mortality in Korea between 1985 and 2010. Endocrinol. Metab. 2014, 29, 530–535. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016, 26, 1–133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Hwangbo, Y.; Kim, J.M.; Park, Y.J.; Lee, E.K.; Lee, Y.J.; Park, D.J.; Choi, Y.S.; Lee, K.D.; Sohn, S.Y.; Kim, S.W.; et al. Long-Term Recurrence of Small Papillary Thyroid Cancer and Its Risk Factors in a Korean Multicenter Study. J. Clin. Endocrinol. Metab. 2017, 102, 625–633. [Google Scholar] [CrossRef] [Green Version]
  7. Chan, S.; Karamali, K.; Kolodziejczyk, A.; Oikonomou, G.; Watkinson, J.; Paleri, V.; Nixon, I.; Kim, D. Systematic Review of Recurrence Rate after Hemithyroidectomy for Low-Risk Well-Differentiated Thyroid Cancer. Eur. Thyroid J. 2020, 9, 73–84. [Google Scholar] [CrossRef]
  8. Redlich, A.; Luster, M.; Lorenz, K.; Lessel, L.; Rohrer, T.R.; Schmid, K.W.; Frühwald, M.C.; Vorwerk, P.; Kuhlen, M. Age, American Thyroid Association Risk Group, and Response to Therapy Are Prognostic Factors in Children With Differentiated Thyroid Cancer. J. Clin. Endocrinol. Metab. 2022, 107, e165–e177. [Google Scholar] [CrossRef]
  9. Rangel-Pozzo, A.; Sisdelli, L.; Cordioli, M.I.V.; Vaisman, F.; Caria, P.; Mai, S.; Cerutti, J.M. Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations. Cancers 2020, 12, 3146. [Google Scholar] [CrossRef]
  10. Crawshaw, M. Psychosocial oncofertility issues faced by adolescents and young adults over their lifetime: A review of the research. Hum. Fertil. Camb 2013, 16, 59–63. [Google Scholar] [CrossRef]
  11. Alexander, E.K.; Pearce, E.N.; Brent, G.A.; Brown, R.S.; Chen, H.; Dosiou, C.; Grobman, W.A.; Laurberg, P.; Lazarus, J.H.; Mandel, S.J.; et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017, 27, 315–389. [Google Scholar] [CrossRef] [Green Version]
  12. Kim, K.J.; Song, J.E.; Kim, J.Y.; Bae, J.H.; Kim, N.H.; Yoo, H.J.; Kim, H.Y.; Seo, J.A.; Kim, N.H.; Lee, J.; et al. Effects of radioactive iodine treatment on cardiovascular disease in thyroid cancer patients: A nationwide cohort study. Ann. Transl. Med. 2020, 8, 1235. [Google Scholar] [CrossRef]
  13. Orosco, R.K.; Hussain, T.; Noel, J.E.; Chang, D.C.; Dosiou, C.; Mittra, E.; Divi, V.; Orloff, L.A. Radioactive iodine in differentiated thyroid cancer: A national database perspective. Endocr. Relat. Cancer 2019, 26, 795–802. [Google Scholar] [CrossRef] [PubMed]
  14. Ko, K.Y.; Yen, R.F.; Lin, C.L.; Cheng, M.F.; Huang, W.S.; Kao, C.H. Pregnancy Outcome After I-131 Therapy for Patients With Thyroid Cancer: A Nationwide Population-Based Cohort Study. Medicine 2016, 95, e2685. [Google Scholar] [CrossRef] [PubMed]
  15. Ahn, J.; Jeon, M.J.; Song, E.; Kim, T.Y.; Kim, W.B.; Shong, Y.K.; Kim, W.G. Quality of Life in Patients with Papillary Thyroid Microcarcinoma According to Treatment: Total Thyroidectomy with or without Radioactive Iodine Ablation. Endocrinol. Metab. 2020, 35, 115–121. [Google Scholar] [CrossRef] [PubMed]
  16. Van Nostrand, D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid 2009, 19, 1381–1391. [Google Scholar] [CrossRef] [PubMed]
  17. Sawka, A.M.; Lakra, D.C.; Lea, J.; Alshehri, B.; Tsang, R.W.; Brierley, J.D.; Straus, S.; Thabane, L.; Gafni, A.; Ezzat, S.; et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin. Endocrinol. 2008, 69, 479–490. [Google Scholar] [CrossRef]
  18. Piek, M.W.; Postma, E.L.; van Leeuwaarde, R.; de Boer, J.P.; Bos, A.M.E.; Lok, C.; Stokkel, M.; Filipe, M.D.; van der Ploeg, I.M.C. The Effect of Radioactive Iodine Therapy on Ovarian Function and Fertility in Female Thyroid Cancer Patients: A Systematic Review and Meta-Analysis. Thyroid 2021, 31, 658–668. [Google Scholar] [CrossRef]
  19. Wu, J.X.; Young, S.; Ro, K.; Li, N.; Leung, A.M.; Chiu, H.K.; Harari, A.; Yeh, M.W. Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer. Thyroid 2015, 25, 133–138. [Google Scholar] [CrossRef] [Green Version]
  20. Kim, H.O.; Lee, K.; Lee, S.M.; Seo, G.H. Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer. JAMA Intern. Med. 2020, 180, 54–61. [Google Scholar] [CrossRef]
  21. Yasuoka, T.; Iwama, N.; Ota, K.; Harada, M.; Hasegawa, J.; Yaegashi, N.; Sugiyama, T.; Suzuki, N.; Osuga, Y. Pregnancy outcomes in children, adolescents, and young adults that survived cancer: A nationwide survey in Japan. J. Obstet. Gynaecol. Res. 2021, 47, 3352–3361. [Google Scholar] [CrossRef]
  22. Nies, M.; Cantineau, A.E.P.; Arts, E.G.J.M.; van den Berg, M.H.; van Leeuwen, F.E.; Muller Kobold, A.C.; Klein Hesselink, M.S.; Burgerhof, J.G.M.; Brouwers, A.H.; van Dam, E.W.C.M.; et al. Long-Term Effects of Radioiodine Treatment on Female Fertility in Survivors of Childhood Differentiated Thyroid Carcinoma. Thyroid 2020, 30, 1169–1176. [Google Scholar] [CrossRef]
  23. Wells, G.A.S.B.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed on 16 December 2021).
  24. Solmi, M.; Firth, J.; Miola, A.; Fornaro, M.; Frison, E.; Fusar-Poli, P.; Dragioti, E.; Shin, J.I.; Carvalho, A.F.; Stubbs, B.; et al. Disparities in cancer screening in people with mental illness across the world versus the general population: Prevalence and comparative meta-analysis including 4,717,839 people. Lancet Psychiatry 2020, 7, 52–63. [Google Scholar] [CrossRef]
  25. Blackburn, B.E.; Ganz, P.A.; Rowe, K.; Snyder, J.; Wan, Y.; Deshmukh, V.; Newman, M.; Fraser, A.; Smith, K.; Herget, K.; et al. Reproductive and gynecological complication risks among thyroid cancer survivors. J. Cancer Surviv. 2018, 12, 702–711. [Google Scholar] [CrossRef]
  26. Beksaç, K.; Aktoz, F.; Örgül, G.; Çelik, H.T.; Özgü-Erdinç, A.S.; Beksaç, M.S. Pregnancy in papillary thyroid cancer survivors. J. Turk. Ger. Gynecol. Assoc. 2018, 19, 94–97. [Google Scholar] [CrossRef] [PubMed]
  27. Hartnett, K.P.; Ward, K.C.; Kramer, M.R.; Lash, T.L.; Mertens, A.C.; Spencer, J.B.; Fothergill, A.; Howards, P.P. The risk of preterm birth and growth restriction in pregnancy after cancer. Int. J. Cancer 2017, 141, 2187–2196. [Google Scholar] [CrossRef] [PubMed]
  28. Metallo, M.; Groza, L.; Brunaud, L.; Klein, M.; Weryha, G.; Feigerlova, E. Long-Term Quality of Life and Pregnancy Outcomes of Differentiated Thyroid Cancer Survivors Treated by Total Thyroidectomy and I(131) during Adolescence and Young Adulthood. Int. J. Endocrinol. 2016, 2016, 7586482. [Google Scholar] [CrossRef] [Green Version]
  29. Fard-Esfahani, A.; Hadifar, M.; Fallahi, B.; Beiki, D.; Eftekhari, M.; Saghari, M.; Takavar, A. Radioiodine treatment complications to the mother and child in patients with differentiated thyroid carcinoma. Hell. J. Nucl. Med. 2009, 12, 37–40. [Google Scholar]
  30. Garsi, J.P.; Schlumberger, M.; Rubino, C.; Ricard, M.; Labbé, M.; Ceccarelli, C.; Schvartz, C.; Henri-Amar, M.; Bardet, S.; de Vathaire, F. Therapeutic administration of 131I for differentiated thyroid cancer: Radiation dose to ovaries and outcome of pregnancies. J. Nucl. Med. 2008, 49, 845–852. [Google Scholar] [CrossRef] [Green Version]
  31. Brandão, C.D.; Miranda, A.E.; Corrêa, N.D.; Sieiro Netto, L.; Corbo, R.; Vaisman, M. Radioiodine therapy and subsequent pregnancy. Arq. Bras. Endocrinol. Metabol. 2007, 51, 534–540. [Google Scholar] [CrossRef] [Green Version]
  32. do Rosário, P.W.; Barroso, A.L.; Rezende, L.L.; Padrão, E.L.; Borges, M.A.; Purisch, S. Malformations in the offspring of women with thyroid cancer treated with radioiodine for the ablation of thyroid remnants. Arq. Bras. Endocrinol. Metabol. 2006, 50, 930–933. [Google Scholar] [CrossRef] [Green Version]
  33. Balenović, A.; Vlasić, M.; Sonicki, Z.; Bodor, D.; Kusić, Z. Pregnancy outcome after treatment with radioiodine for differentiated thyroid carcinoma. Coll. Antropol. 2006, 30, 743–748. [Google Scholar]
  34. Bal, C.; Kumar, A.; Tripathi, M.; Chandrashekar, N.; Phom, H.; Murali, N.R.; Chandra, P.; Pant, G.S. High-dose radioiodine treatment for differentiated thyroid carcinoma is not associated with change in female fertility or any genetic risk to the offspring. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63, 449–455. [Google Scholar] [CrossRef] [PubMed]
  35. Chow, S.M.; Yau, S.; Lee, S.H.; Leung, W.M.; Law, S.C. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: No deleterious effect after radioactive iodine treatment. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59, 992–1000. [Google Scholar] [CrossRef] [PubMed]
  36. Dottorini, M.E.; Lomuscio, G.; Mazzucchelli, L.; Vignati, A.; Colombo, L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J. Nucl. Med. 1995, 36, 21–27. [Google Scholar] [PubMed]
  37. Vini, L.; Hyer, S.; Al-Saadi, A.; Pratt, B.; Harmer, C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad. Med. J. 2002, 78, 92–93. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Lin, J.D.; Wang, H.S.; Weng, H.F.; Kao, P.F. Outcome of pregnancy after radioactive iodine treatment for well differentiated thyroid carcinomas. J. Endocrinol. Investig. 1998, 21, 662–667. [Google Scholar] [CrossRef] [PubMed]
  39. Ayala, C.; Navarro, E.; Rodríguez, J.R.; Silva, H.; Venegas, E.; Astorga, R. Conception after iodine-131 therapy for differentiated thyroid cancer. Thyroid 1998, 8, 1009–1011. [Google Scholar] [CrossRef]
  40. Smith, M.B.; Xue, H.; Takahashi, H.; Cangir, A.; Andrassy, R.J. Iodine 131 thyroid ablation in female children and adolescents: Long-term risk of infertility and birth defects. Ann. Surg. Oncol. 1994, 1, 128–131. [Google Scholar] [CrossRef]
  41. Casara, D.; Rubello, D.; Saladini, G.; Piotto, A.; Pelizzo, M.R.; Girelli, M.E.; Busnardo, B. Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: Potential risks and recommendations. Eur. J. Nucl. Med. 1993, 20, 192–194. [Google Scholar] [CrossRef]
  42. Liu, D.; Wei, Y.; Zhao, Y.; Li, R.; Yan, J.; Qiao, J. Obstetric outcomes in thyroid cancer survivors: A retrospective cohort study. Int. J. Gynaecol. Obstet. 2021, 155, 119–124. [Google Scholar] [CrossRef]
  43. Li, Z.; Qiu, Y.; Fei, Y.; Xing, Z.; Zhu, J.; Su, A. Prevalence of and risk factors for hypothyroidism after hemithyroidectomy: A systematic review and meta-analysis. Endocrine 2020, 70, 243–255. [Google Scholar] [CrossRef]
  44. McGriff, N.J.; Csako, G.; Gourgiotis, L.; Lori, C.G.; Pucino, F.; Sarlis, N.J. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann. Med. 2002, 34, 554–564. [Google Scholar] [CrossRef] [PubMed]
  45. Krassas, G.E.; Pontikides, N.; Kaltsas, T.; Papadopoulou, P.; Paunkovic, J.; Paunkovic, N.; Duntas, L.H. Disturbances of menstruation in hypothyroidism. Clin. Endocrinol. 1999, 50, 655–659. [Google Scholar] [CrossRef] [PubMed]
  46. Bérard, A.; Abbas-Chorfa, F.; Kassai, B.; Vial, T.; Nguyen, K.A.; Sheehy, O.; Schott, A.M. The French Pregnancy Cohort: Medication use during pregnancy in the French population. PLoS ONE 2019, 14, e0219095. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Gindler, J.; Li, Z.; Berry, R.J.; Zheng, J.; Correa, A.; Sun, X.; Wong, L.; Cheng, L.; Erickson, J.D.; Wang, Y.; et al. Folic acid supplements during pregnancy and risk of miscarriage. Lancet 2001, 358, 796–800. [Google Scholar] [CrossRef]
  48. Okui, T. An Analysis of the Trend of Fetal Mortality Rates among Working and Jobless Households in Japan, 1995–2019. Int. J. Environ. Res. Public Health 2021, 18, 4810. [Google Scholar] [CrossRef]
  49. Braem, M.G.; Onland-Moret, N.C.; Schouten, L.J.; Kruitwagen, R.F.; Lukanova, A.; Allen, N.E.; Wark, P.A.; Tjønneland, A.; Hansen, L.; Braüner, C.M.; et al. Multiple miscarriages are associated with the risk of ovarian cancer: Results from the European Prospective Investigation into Cancer and Nutrition. PLoS ONE 2012, 7, e37141. [Google Scholar]
  50. Paul, P.J. Maternal Age at Marriage and Adverse Pregnancy Outcomes: Findings from the India Human Development Survey, 2011–2012. Pediatr. Adolesc. Gynecol. 2018, 31, 620–624. [Google Scholar] [CrossRef]
  51. World Health Organization Global Survey on Maternal and Perinatal Health. Available online: https://www.who.int/reproductivehealth/topics/best_practices/globalsurveyoriginal/en/ (accessed on 16 December 2021).
  52. Centers for Disease Control and Prevention. Monthly Vital Statistics Report. Available online: https://www.cdc.gov/nchs/data/mvsr/supp/mv43_05s.pdf (accessed on 16 December 2021).
  53. Statistics Korea. Available online: https://kostat.go.kr/portal/korea/kor_nw/1/2/3/index.board?bmode=read&bSeq=&aSeq=377055&pageNo=2&rowNum=10&navCount=10&currPg=&searchInfo=&sTarget=title&sTxt=) (accessed on 16 December 2021).
  54. Kyozuka, H.; Yasuda, S.; Murata, T.; Fukuda, T.; Yamaguchi, A.; Kanno, A.; Sato, A.; Ogata, Y.; Hosoya, M.; Yasumura, S.; et al. Adverse obstetric outcomes in early-diagnosed gestational diabetes mellitus: The Japan Environment and Children’s Study. J. Diabetes Investig. 2021, 12, 2071–2079. [Google Scholar] [CrossRef]
  55. An Official Website of the European Union. EUROCAT. Available online: https://eu-rd-platform.jrc.ec.europa.eu/eurocat/eurocat-data/prevalence/export_en (accessed on 16 December 2021).
  56. Seo, G.H.; Kim, T.H.; Chung, J.H. Antithyroid Drugs and Congenital Malformations: A Nationwide Korean Cohort Study. Ann. Intern. Med. 2018, 168, 405–413. [Google Scholar] [CrossRef]
  57. Sawka, A.M.; Lea, J.; Alshehri, B.; Straus, S.; Tsang, R.W.; Brierley, J.D.; Thabane, L.; Rotstein, L.; Gafni, A.; Ezzat, S.; et al. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin. Endocrinol. 2008, 68, 610–617. [Google Scholar] [CrossRef]
  58. Bourcigaux, N.; Rubino, C.; Berthaud, I.; Toubert, M.E.; Donadille, B.; Leenhardt, L.; Petrot-Keller, I.; Brailly-Tabard, S.; Fromigué, J.; de Vathaire, F.; et al. Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma. Hum. Reprod. 2018, 33, 1408–1416. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Hyer, S.; Vini, L.; O’Connell, M.; Pratt, B.; Harmer, C. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin. Endocrinol. 2002, 56, 755–758. [Google Scholar] [CrossRef] [PubMed]
  60. Mazzaferri, E.L. Gonadal damage from 131I therapy for thyroid cancer. Clin. Endocrinol. 2002, 57, 313–314. [Google Scholar] [CrossRef] [PubMed]
  61. Anderson, C.; Engel, S.M.; Weaver, M.A.; Zevallos, J.P.; Nichols, H.B. Birth rates after radioactive iodine treatment for differentiated thyroid cancer. Int. J. Cancer 2017, 141, 2291–2295. [Google Scholar] [CrossRef]
  62. Yaish, I.; Azem, F.; Gutfeld, O.; Silman, Z.; Serebro, M.; Sharon, O.; Shefer, G.; Limor, R.; Stern, N.; Tordjman, K.M. A Single Radioactive Iodine Treatment Has a Deleterious Effect on Ovarian Reserve in Women with Thyroid Cancer: Results of a Prospective Pilot Study. Thyroid 2018, 28, 522–527. [Google Scholar] [CrossRef]
  63. Navarro, P.; Rocher, S.; Miró-Martínez, P.; Oltra-Crespo, S. Radioactive iodine and female fertility. Sci. Rep. 2022, 12, 3704. [Google Scholar] [CrossRef]
  64. Oktay, K.; Harvey, B.E.; Partridge, A.H.; Quinn, G.P.; Reinecke, J.; Taylor, H.S.; Wallace, W.H.; Wang, E.T.; Loren, A.W. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J. Clin. Oncol. 2018, 36, 1994–2001. [Google Scholar] [CrossRef]
  65. Iijima, S. Effects of fetal involvement of inadvertent radioactive iodine therapy for the treatment of thyroid diseases during an unsuspected pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2021, 259, 53–59. [Google Scholar] [CrossRef]
  66. International Commission on Radiological Protection. Radiation effects in the embryo and fetus. In ICRP Publication 103; Valentin, J., Ed.; Elsevier: Amsterdam, The Netherlands, 2007; Volume 37, p. 57. [Google Scholar]
  67. Wassner, A.J.; Smith, J.R. Hypothyroidism. In Nelson Textbook of Pediatrics, 21st ed.; Kliegman, R.M., St. Geme, J.W., III, Eds.; Elsevier: Amsterdam, The Netherlands, 2019; pp. 2914–2922. [Google Scholar]
  68. Berg, G.E.; Nyström, E.H.; Jacobsson, L.; Lindberg, S.; Lindstedt, R.G.; Mattsson, S.; Niklasson, C.A.; Norén, A.H.; Westphal, O.G. Radioiodine treatment of hyperthyroidism in a pregnant woman. J. Nucl. Med. 1998, 39, 357–361. [Google Scholar]
  69. Berg, G.E.; Jacobsson, L.; Nyström, E.; Gleisner, K.S.; Tennvall, J. Consequences of inadvertent radioactive treatment of Graves’ disease and thyroid cancer in undiagnosed pregnancy. Can we rely on routine pregnancy testing? Acta Oncol. 2008, 47, 145–149. [Google Scholar] [CrossRef]
  70. Otake, M.; Schull, W.J. Radiation-related brain damage and growth retardation among the prenatally exposed atomic bomb survivors. Int. J. Radiat. Biol. 1998, 74, 159–171. [Google Scholar] [CrossRef] [PubMed]
  71. Centers for Disease Control and Prevention. Radiation and Pregnancy: A Fact Sheet for Clinicians. Available online: https://www.cdc.gov/nceh/radiation/emergencies/prenatalphysician.htm (accessed on 11 April 2022).
  72. Buls, N.; Covens, P.; Nieboer, K.; Van Schuerbeek, P.; Devacht, P.; Eloot, L.; de Mey, J. Dealing with pregnancy in radiology: A thin line between science, social and regulatory aspects. JBR BTR 2009, 92, 271–279. [Google Scholar] [PubMed]
  73. Radiation Protection of Pregnant Women in Nuclear Medicine. IAEA Radiation Protection of Patients (RPOP). Available online: https://www.iaea.org/resources/rpop/health-professionals/nuclear-medicine/pregnant-women (accessed on 11 April 2022).
  74. International Commission on Radiological Protection. Pregnancy and medical radiation. In ICRP Publication 84; Valentin, J., Ed.; Elsevier: Amsterdam, The Netherlands, 2000; Volume 30, pp. 1–43. [Google Scholar]
Cancers 14 02382 g001 550
Figure 1. Scheme of the search strategy.
Figure 1. Scheme of the search strategy.
Cancers 14 02382 g001
Cancers 14 02382 g002 550
Figure 2. Effect of treatment of differentiated thyroid cancer on miscarriage. (A) Event rate among cases of pregnancy and (B) the OR between patients with DTC and controls without differentiated thyroid cancer; * abortion. Studies referenced in the figure are: [21,22,25,26,28,29,30,31,32,33,34,35,36,37,39,40,41,42].
Figure 2. Effect of treatment of differentiated thyroid cancer on miscarriage. (A) Event rate among cases of pregnancy and (B) the OR between patients with DTC and controls without differentiated thyroid cancer; * abortion. Studies referenced in the figure are: [21,22,25,26,28,29,30,31,32,33,34,35,36,37,39,40,41,42].
Cancers 14 02382 g002
Cancers 14 02382 g003 550
Figure 3. Effect of treatment of DTC on preterm labor. (A) Event rate among cases of pregnancy and (B) the OR between patients with DTC and controls without DTC. Studies referenced: [20,21,25,26,27,30,31,32,34,35,36,37,38,40,42].
Figure 3. Effect of treatment of DTC on preterm labor. (A) Event rate among cases of pregnancy and (B) the OR between patients with DTC and controls without DTC. Studies referenced: [20,21,25,26,27,30,31,32,34,35,36,37,38,40,42].
Cancers 14 02382 g003
Cancers 14 02382 g004 550
Figure 4. Effect of treatment of DTC on congenital anomalies. (A) Event rate among cases of pregnancy and (B) the OR between patients with DTC and controls without DTC. Studies referenced: [20,22,26,28,29,30,31,32,33,34,35,36,37,38,39,40,41].
Figure 4. Effect of treatment of DTC on congenital anomalies. (A) Event rate among cases of pregnancy and (B) the OR between patients with DTC and controls without DTC. Studies referenced: [20,22,26,28,29,30,31,32,33,34,35,36,37,38,39,40,41].
Cancers 14 02382 g004
Cancers 14 02382 g005 550
Figure 5. Effect of RAIT on adverse pregnancy outcomes. (A) Miscarriage or abortion, (B) preterm labor, and (C) congenital anomalies. * The study was classified as a case series design because one arm data of patients with thyroid cancer was used in the study. Studies referenced: [14,20,22,26,28,29,30,31,32,33,34,35,36,38,39,40,41].
Figure 5. Effect of RAIT on adverse pregnancy outcomes. (A) Miscarriage or abortion, (B) preterm labor, and (C) congenital anomalies. * The study was classified as a case series design because one arm data of patients with thyroid cancer was used in the study. Studies referenced: [14,20,22,26,28,29,30,31,32,33,34,35,36,38,39,40,41].
Cancers 14 02382 g005
Cancers 14 02382 g006 550
Figure 6. The risk of adverse pregnancy outcomes in patients with an interval of 1 year or more between conception and RAIT. Effect of RAIT on adverse pregnancy outcomes. (A) Miscarriage or abortion, (B) preterm labor, and (C) congenital anomalies. * The study was classified as a case series design because one arm data of patients with thyroid cancer was used in the study. Studies referenced: [14,20,22,26,28,29,30,31,32,33,34,35,36,38,39,40,41].
Figure 6. The risk of adverse pregnancy outcomes in patients with an interval of 1 year or more between conception and RAIT. Effect of RAIT on adverse pregnancy outcomes. (A) Miscarriage or abortion, (B) preterm labor, and (C) congenital anomalies. * The study was classified as a case series design because one arm data of patients with thyroid cancer was used in the study. Studies referenced: [14,20,22,26,28,29,30,31,32,33,34,35,36,38,39,40,41].
Cancers 14 02382 g006
Table
Table 1. Study characteristics of the included studies.
Table 1. Study characteristics of the included studies.
Study
[Reference]		RegionStudy DesignParticipantsNo. of Total
Participants		No. of Patients with RAIAgePregnant Outcomes
Liu et al. 2021 [42]ChinaCase-control designData form the University Hospital in
Beijing		562 women
Cases:
154 women with thyroid cancer Controls:
308 matched controls without thyroid cancer		5 womenMedian age at pregnancy:
Patients with thyroid cancer: 33
Controls: 32		Pregnant women with thyroid cancer compared to those without thyroid cancer
Preterm delivery: 5.84% vs. 7.47%
Adjusted OR with 95% CI
(Reference group: women without thyroid cancer)
Preterm delivery: 0.73 (0.32–1.67)
Yasuoka et al. 2021
[21]		JapanCase series designData from major
tertiary institutions
in Japan		341 women with thyroid cancerNANAMiscarriage: 5 of 314 pregnancies
Preterm delivery: 25 of 314 pregnancies
Kim et al. 2020
[20]		KoreaCase series design *Data from Health
Insurance Review
and Assessment database		10,842 pregnancies in women with thyroid cancer
Cases
:4884 with RAITControls:
5958 without RAIT		4884 pregnanciesMean (SD): 33.3
(4.4)		Pregnant women without RAI compared to those with RAI
Abortion: 30.7% vs. 32.1%
Preterm deliveries: 12.8% vs. 12.9%
Congenital malformations: 8.9% vs. 9.0%
Adjusted OR with 95% CI
(Reference group: patients with RAI dose ≤1.11 GBq)
Abortion
1.12–3.7 GBq: 1.11 (0.91–1.36)
≥3.8 GBq: 1.02 (0.85–1.22)
Preterm delivery
1.12–3.7 GBq: 0.79 (0.58–1.08)
≥3.8 GBq: 0.82 (0.63–1.08)
Congenital malformation
1.12–3.7 GBq: 1.06 (0.72–1.56)
≥3.8 GBq: 1.08 (0.76–1.52)
Nies et al. 2020
[22]		The NetherlandsCase series designA nationwide, long-term follow-up study on childhood differentiated thyroid cancer in the Netherlands56 women with thyroid cancer
(64 pregnancies)		56 womenMedian age at first pregnancy (IQR)
25.5 (22.5–30.0)		Miscarriage: 8 of 56 women (64 pregnancies) after RAIT
Congenital malformation: 7 of 45 pregnancies after RAIT
Blackburn et al. 2018
[25]		USACase-control designThe Utah Population
Database, which links data from the Utah Cancer
Registry 		9753 women Cases:
1832 women with thyroid cancer
Controls
7921 matched control without thyroid cancer)		947 womenMedian age 36Miscarriage: 25 of 1832 women by 1–5 years after thyroid cancer diagnosis and 63 of 7921 women in general population cohort
Preterm deliveries: 57 of 1832 women by 1–5 years after thyroid cancer diagnosis and 175 of 7921 women in general population cohort
Beksaç et al. 2018
[26]		TurkeyCase series designThe clinical records of 8 pregnant women who received treatment for PTC before their pregnancy8 women with thyroid cancer8 womenMean age 34.3 years Miscarriage: 1 of 8 pregnancies after thyroid cancer treatment
Preterm delivery: 1 or 7 pregnancies after thyroid cancer treatment
Congenital malformation: 1 or 7 pregnancies after thyroid cancer treatment
Hartnett et al. 2017
[27]		USACase-control designCancer registries
in the states of Georgia,
North Carolina, and Tennessee		4,032,219 women
Cases:
970 women with thyroid cancer Controls:
4,031,349 matched control without cancer		NANAAdjusted risk ratio (95% CI) for preterm deliveries:
1.0 (0.8, 1.2)
Metallo et al. 2016
[28]		FranceCase series design *Data form the University Hospital in Nancy45 women with thyroid cancer
RAIT
≤3.85 GBq: 18 women
>3.85 GBq: 27 women		45 womenMean (SD)
Patients with RAIT ≤3.85 GBq: 27.7 (6.7)
>3.85 GBq: 36.1 (11.1)		Miscarriage:
1of 18 patients with RAIT ≤3.85 GBq and 5 of 27 patients with RAIT >3.85 GBq
Congenital anomaly was not observed in this study.
Ko et al. 2016 [14]TaiwanCase series design *The National
Health Insurance Research Database in Taiwan		1491 women with thyroid cancer
Cases:
775 patients with RAIT
Controls:
716 without RAIT		775 womenNAAbortion: 71 of 716 patients with RAIT and 85 of 775 patients without RAIT
Preterm delivery: 29 of 716 patients with RAIT and 41 of 775 patients without RAIT
Adjusted HR (95% CI) (patients without RAIT vs. patients with RAIT)
Abortion: 0.67 (0.49–0.93)
Preterm delivery: 1.32 (0.81–2.15)
Fard-Esfahani et al. 2009
[29]		IranCase series design *Data from one institution in Iran227 pregnancies in women with thyroid cancer
Cases:
126 pregnancies after RAIT
Controls:
101 pregnancies before RAIT		126 pregnancies in 100 womenNAMiscarriage: 13 of 126 pregnancies after I131 treatment
(10/100 women) and 17 of 101 pregnancy before thyroid cancer treatment
Garsi et al. 2008
[30]		France and ItalyCase-control designData from three institutions in France and one institution in Italy2673 pregnancies in 1126 patients with thyroid cancer
Cases:
595 pregnancies after thyroid cancer treatment
Controls:
2078 pregnancies before thyroid cancer treatment,		483 pregnanciesNAMiscarriage: 193 of 1854 pregnancies before thyroid cancer treatment, 92 of 475 pregnancies after thyroid cancer treatment (75 of 389 pregnancies after I131 treatment)
Preterm delivery: 114 of 1633 live births before thyroid cancer treatment, 44 of 376 live births after thyroid cancer treatment (40 of 309 live births after I131 treatment)
Congenital malformation: 68 of 1633 live births before thyroid cancer treatment, 11 of 376 live births after thyroid cancer treatment (9 of 309 live births after I131 treatment)
Brandao et al. 2007
[31]		BrazilCase-control designData from three institutions in Brazil126 pregnancies Cases:
66 pregnancies after RAIT
Controls:
60 pregnancies in healthy women		66 pregnancies
(48 women)		NAAbortion: 6/66 pregnancies after RAIT and 7/60 pregnancies in healthy women
Preterm delivery: 1/66 pregnancies after RAIT and 6/60 pregnancies in healthy women Congenital malformation: 1/66 pregnancies after RAIT. Congenital malformation was not observed in healthy women
Rosário et al. 2006
[32]		BrazilCase series designData from one institution in Brazil78 pregnancies after RAIT78 pregnanciesNAMiscarriage: 4 of 78 pregnancies after RAIT
Preterm delivery: 3 or 78 pregnancies after RAIT
Congenital malformation: 1 or 78 pregnancies after RAIT
Balenovic et al. 2006
[33]		CroatiaCase series designData from one institution in Croatia26 women after RAIT
(40 pregnancies)		26 women (40 pregnancies)NAMiscarriage: 2 of 26 women after RAIT (5 of 40 pregnancies)
Congenital malformation was not observed (0/35 births)
Bal et al. 2005 [34]IndiaCase series designData from one institution in India50 pregnancies after RAIT in 40 women50 pregnanciesNAMiscarriage: 3 of 50 pregnancies after RAIT
Preterm delivery: 1 or 50 pregnancies after RAIT
Congenital malformation was not observed
Chow et al. 2004
[35]		ChinaCase series design *Data from one institution in China263 pregnancies in 104 women after thyroid cancer treatment
Cases:
143 pregnancies after RAIT
Controls:
110 pregnancies without RAIT		143 pregnanciesMean age (SD) at pregnancy:
No RAI: 26.5 (5.4)
RAI scanning dose: 30.7 (4.7)RAI ablation does: 31.4 (4.6)		Miscarriage: 18 of 143 pregnancies with RAIT (13 of 116 pregnancies with I131 ablative dose) and 7 of 110 pregnancies without RAIT
Preterm delivery: 11 of 143 pregnancies with RAIT (7 of 116 pregnancies with I131 ablative dose) and 1 of 110 pregnancies without RAITCongenital malformation was not observed
Vini et al. 2002
[37]		UKCase series designData from one institution in UK441 pregnancies after thyroid cancer treatment (276 women)441 pregnancies
(276 women)		NAMiscarriage:14 of 441 pregnancies after RAIT
Preterm delivery: 4 of 427 pregnancies after RAIT
Congenital malformation: 0 of 427 pregnancies after RAIT
Lin et al. 1998 [38]TaiwanCase series designData from one institution in Taiwan58 pregnancies after I131 treatment (37 women)58 pregnanciesMean age at pregnancy (SD): 27.97 (3.49)Miscarriage: 8 of 58 pregnancies after RAIT Preterm delivery: 3 of 58 pregnancies after RAIT
Congenital malformation: 1 of 58 pregnancies after RAIT
Ayala et al. 1998
[39]		SpainCase series designData from one institution in Spain39 pregnancies after I131 treatment (26 women)39 pregnanciesMean age at the time of the first pregnancy: 26.9Miscarriage: 2 of 39 pregnancies after RAIT Congenital malformation: 4 of 39 pregnancies after RAIT
Dottorini et al. 1995
[36]		ItalyCase series design *Data from one institution in Italy84 pregnancies in 64 women with thyroid cancer
Cases:
65 pregnancies after RAIT
Controls:
19 pregnancies without RAIT		65 pregnanciesNAMiscarriage: 3 of 65 pregnancies with RAIT and 1 of 19 pregnancies without RAIT
Preterm delivery: 2 of 65 pregnancies with RAIT and 0 of 19 pregnancies without RAIT
Congenital malformation: 1 of 65 pregnancies with RAIT and 0 of 19 pregnancies without RAIT
Smith et al. 1994
[40]		USACase series designReview of The University of Texas M. D. Anderson
Cancer Center Tumor Registry		69 pregnancies in 32 women after RAIT 69 pregnanciesMean age at I131 treatment: 18.3Miscarriage: 3 of 69 pregnancies after RAIT
Preterm delivery: 4 of 69 pregnancies after RAIT
Congenital malformation: 2 of 69 pregnancies after RAIT
Casara et al. 1993
[41]		ItalyCase series designData from one institution in Italy70 women with RAIT70 womenMean age (SD) at pregnancy: 29 (4.2)Miscarriage: 2 of 75 pregnancies after RAIT
Congenital malformation: 1 of 73 live births
* The study was classified as a case series design because one arm data of patients with thyroid cancer was used in the study.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Moon, S.; Yi, K.H.; Park, Y.J. Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis. Cancers 2022, 14, 2382. https://doi.org/10.3390/cancers14102382

AMA Style

Moon S, Yi KH, Park YJ. Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis. Cancers. 2022; 14(10):2382. https://doi.org/10.3390/cancers14102382

Chicago/Turabian Style

Moon, Shinje, Ka Hee Yi, and Young Joo Park. 2022. "Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis" Cancers 14, no. 10: 2382. https://doi.org/10.3390/cancers14102382

APA Style

Moon, S., Yi, K. H., & Park, Y. J. (2022). Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis. Cancers, 14(10), 2382. https://doi.org/10.3390/cancers14102382

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop